In one pilot study, seven cancer patients had 31% higher energy intake with i.v. ghrelin than with placebo (5 pmol kg−1 min−1 for 180 min equals 3 μg kg−1), with no adverse effects (Neary et al, 2004). The gene discussed is GHRL; the disease is cancer.